Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope
- 13 June 2007
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 96 (1), 3-7
- https://doi.org/10.1002/jso.20656
Abstract
Introduction Papillary cancer is the most common neoplasm of the thyroid. The mainstay of treatment is thyroidectomy, but most patients are additionally treated with radioactive iodine (RAI). Its utility is controversial. This study seeks to determine whether RAI use affects patient outcome and to identify specific cohorts of patients that benefit from its use. Methods The Surveillance, Epidemiology, and End Results (SEER) database is a large-scale sample of approximately 14% of the US population. It was used to identify patients with papillary carcinoma of the thyroid. Statistical analyses were used to compare prognostic factors such as lymph node status, age, tumor size, and treatment with RAI. Results A total of 14,545 patients were identified in SEER as having papillary cancer of the thyroid. Multivariate analysis showed significantly worse outcome in patients with age>45 years, tumor size >2 cm, lymph node disease, and distant metastases. Multivariate analysis failed to show RAI significantly affecting mortality. Survival between those not treated with RAI was similar to those whose treatment included it (P = 0.9176). Subgroup analysis identified patients older than 45 years with primary tumors >2 cm and disease in the lymph nodes with distant metastatic disease as the only group positively affected by RAI. Conclusions Despite its widespread use in the treatment of well-differentiated papillary cancer of the thyroid, RAI only affects a survival advantage in older patients with large primary tumors involving the lymph nodes and with distant spread. Treating other patient groups is costly and offers no improvement in outcome. J. Surg. Oncol. 2007; 96:3–7.This publication has 15 references indexed in Scilit:
- A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid CancerJournal of Clinical Endocrinology & Metabolism, 2004
- Unilateral total lobectomy: Is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma?Surgery, 1998
- Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control groupStatistics in Medicine, 1998
- Differentiated Thyroid CancerArchives of Surgery, 1998
- Patterns of failure in differentiated carcinoma of the thyroid based on risk groupsHead & Neck, 1998
- Estimating Causal Effects from Large Data Sets Using Propensity ScoresAnnals of Internal Medicine, 1997
- Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancerThe American Journal of Medicine, 1994
- Impact of Therapy for Differentiated Carcinoma of the Thyroid: An Analysis of 706 Cases*Journal of Clinical Endocrinology & Metabolism, 1983
- Risk factor analysis in differentiated thyroid cancerCancer, 1979
- Radioiodine I-131 therapy in the management of thyroid cancer.A prospective studyCancer, 1977